Immunocore Holdings plc American Depositary Shares

Immunocore announced updated Phase 1/2 trial results for brenetafusp in heavily pretreated advanced melanoma patients, showing a 6-month overall survival rate of 87% and disease control rate of 52%. The 160 mcg dose was selected for the ongoing Phase 3 PRISM-MEL-301 trial. The drug demonstrated clinical benefit in difficult-to-treat subgroups inc...

Immunocore reported Q1 2026 net sales of $106.7 million for KIMMTRAK, representing 14% year-over-year growth. The company presented landmark five-year overall survival data at AACR showing KIMMTRAK doubled the likelihood of being alive at five years (16% vs 8%) for HLA-A*02:01 positive metastatic uveal melanoma patients. The company maintains $84...

Immunocore announced five-year overall survival data for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma, showing 16% OS versus 8% in control arm. The drug doubled survival likelihood and demonstrated durability across poor prognostic subgroups, representing the longest follow-up for any T cell engager in solid tumors.

Immunocore Holdings plc announced that management will participate in multiple investor conferences in March 2026, including TD Cowen Healthcare Conference, Leerink Global Healthcare Conference, Barclays Global Healthcare Conference, UBS Biotech Summit, and Jefferies Biotech on the Beach Summit. The company will present its commercial-stage biote...

Immunocore Holdings plc announced it will report Q4 and full year 2025 financial results on February 25, 2026, followed by a teleconference and webcast. The commercial-stage biotechnology company is advancing its ImmTAX platform for cancer, infectious diseases, and autoimmune diseases, with KIMMTRAK approved for unresectable or metastatic uveal m...